Home › Hereditary Sensory and Autonomic Neuropathies › Colorado
Hereditary Sensory and Autonomic Neuropathies clinical trials in Colorado
7 studies for Hereditary Sensory and Autonomic Neuropathies are looking for participants at sites in Colorado.
Cities in Colorado
Study of ACR-2316 in Specific Advanced Solid Tumors
- Denver Health One, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06667141Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of Colorado, Aurora
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 10, 2026 · NCT07175038A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- University of Colorado Cancer Center, Aurora
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Rocky Mountain Cancer Centers, Lone Tree
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07558733Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
- Rocky Mountain Cancer Centers, Denver
RecruitingObservational study
Ages 1 to 100 · All sexes · Updated Apr 1, 2026 · NCT05868629From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.